Visual Study of Molecular Genotype in Glioma Evolution

Glioma of Brain Clinical Trial

Official title:

A New Strategy for the Visulation of Molecular Genotype in Glioma Evolution Based on the Radiomics and Microomics

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03750890
• Other study ID #: ZWZ2018
• Status: Recruiting
• Start date: January 1, 2019
• Est. completion date: December 31, 2022

Study information

• Verified date: November 2018
• Source: Tongji Hospital
• Contact: Wenzhen Zhu, doctor
• Phone: 8613886018612
• Email: zhuwenzhen8612[@]163.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The key molecular changes in the progression of glioma are closely related to tumor heterogeneity, pathological grade, precision treatment and prognosis of glioma. At present, a visually quantitative assessment criteria about the key molecular typing of glioma is still absent. Based on the previous research, this project intends to establish a multi-dimensional database of glioma from clinical, radiomics and microomics levels. The investigators aim to filter out the specific molecular markers in the progression of glioma and explore the intrinsic connection of radiomics features and microomics molecular markers by using bioinformatics integration analysis and artificial intelligence multiple kernel learning. Thus, the investigators could determine the specific molecular mechanism in the progression of glioma, and establish a visually quantitative assessment system of pre-operative precisive grading, molecular typing discrimination and prognosis prediction. The completion of this project is of great significance for improving molecular diagnostic level of glioma, guiding individualized diagnosis and treatment decisions, and improving the survival rate of patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. postoperative pathological and genetic test confirmed brain glioma;

2. The preoperative Clear and complete multimodal imaging data were collected within 10 days.

Exclusion Criteria:

1. patients who underwent surgery more than 4 weeks after MRI;

2. patients with motion artifacts.

Related Conditions & MeSH terms

• Glioma
• Glioma of Brain

Locations

Country	Name	City	State
China	Zhenxiong Wang	Wuhan	Choose A State Or Province

Sponsors (1)

Lead Sponsor	Collaborator
Tongji Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	radiomics features(the parameters of T1WI, T2WI, DWI, DKI, ASL, ESWAN, DCE, MRS and so on)	the radiomics features(the parameters of T1WI, T2WI, DWI, DKI, ASL, ESWAN, DCE, MRS and so on)in the progression of glioma	through study completion, an average of 3 years
Primary	microomics molecular markers (IDH mutation, 1p/19q status, P53 mutation, TERT and ATRX mutation, EGFR amplification and mutation, MGMT methylation status, PTEN mutation, ZM fusion gene and other gene features)	the key molecular markers (IDH mutation, 1p/19q status, P53 mutation, TERT and ATRX mutation, EGFR amplification and mutation, MGMT methylation status, PTEN mutation, ZM fusion gene and other gene features) in the progression of glioma	through study completion, an average of 3 years